SAR 446268
Alternative Names: SAR-446268Latest Information Update: 31 Mar 2025
At a glance
- Originator Sanofi
- Class Gene therapies
- Mechanism of Action Gene transference; Myotonin protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Myotonic dystrophy
Most Recent Events
- 25 Mar 2025 Preclinical trials in Myotonic dystrophy in France (IV) prior to March 2025
- 12 Mar 2025 Sanofi plans a BrAAVe phase I/II trial for Myotonic dystrophy (In children, In adolescence, In adults) in April 2025 (IV) (NCT06844214)